Brandywine Global Investment Management LLC Lowers Stock Position in United Therapeutics Corporation $UTHR

Brandywine Global Investment Management LLC lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 2.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,751 shares of the biotechnology company’s stock after selling 559 shares during the period. Brandywine Global Investment Management LLC’s holdings in United Therapeutics were worth $7,687,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. CWM LLC boosted its stake in United Therapeutics by 204.3% during the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after acquiring an additional 3,487 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of United Therapeutics in the 1st quarter worth approximately $313,000. LPL Financial LLC grew its stake in shares of United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock worth $7,783,000 after buying an additional 11,007 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of United Therapeutics by 77.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock worth $1,792,000 after buying an additional 2,655 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in United Therapeutics by 17.0% during the 2nd quarter. State of Alaska Department of Revenue now owns 19,532 shares of the biotechnology company’s stock valued at $5,612,000 after buying an additional 2,840 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on UTHR shares. HC Wainwright boosted their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Bank of America upped their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a report on Wednesday, October 29th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $464.76, for a total transaction of $5,112,360.00. Following the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $17,094,337.56. This trade represents a 23.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $470.43, for a total value of $10,584,675.00. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 519,935 shares of company stock worth $224,879,377. Company insiders own 10.30% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $474.82 on Friday. The stock has a market cap of $20.44 billion, a PE ratio of 17.99, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $485.32. The firm has a fifty day moving average price of $439.78 and a 200-day moving average price of $355.90.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the prior year, the firm posted $6.39 EPS. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. On average, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.